A phase 2a clinical trial evaluating RPL554 compared with placebo as add on to LAMA/LABA therapy for the maintenance treatment of severe COPD

Trial Profile

A phase 2a clinical trial evaluating RPL554 compared with placebo as add on to LAMA/LABA therapy for the maintenance treatment of severe COPD

Planning
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs RPL 554 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2018 New trial record
    • 27 Feb 2018 According to a Verona Pharma media release, the company expects to commence this study late in the second half of 2018, with top-line data expected in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top